Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:5105108.
doi: 10.1155/2016/5105108. Epub 2016 May 16.

Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bozong Tang  1 , Jianliang Zhang  2 , Zongguo Yang  2 , Yunfei Lu  2 , Qingnian Xu  2 , Xiaorong Chen  2 , Jiang Lin  3
Affiliations
Review

Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bozong Tang et al. Evid Based Complement Alternat Med. 2016.

Abstract

Background. The complementary and alternative medicines in treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) are controversial. Methods. We searched PubMed, Ovid Embase, Web of Science, Cochrane Library databases, CNKI, Wanfang Database, CBM, VIP, and AMED for randomized controlled trials (RCTs) of moxibustion compared with pharmacological medications in patients with IBS-D. A meta-analysis was performed using both fixed and random-effects models based on heterogeneity across studies. Results. In total, 568 patients in 7 randomized controlled trials were randomly treated with moxibustion and pharmacological medications. The improvement of global IBS-D symptoms and overall scores was significant (P = 0.0001 and P < 0.0001, resp.) in patients treated by moxibustion only compared to pharmacological medications. The specific IBS-D symptoms of abdominal pain, abdominal distension, abnormal stool, and defecation frequency were alleviated in patients treated by moxibustion compared to pharmacological medications, but no significance was found except for abdominal distension and defecation frequency (P = 0.03 and P = 0.02, resp.). There were no serious adverse events related to moxibustion. Conclusions. Moxibustion appears to be effective in treating IBS-D compared with pharmacological medications. However, further large, rigorously designed trials are warranted due to insufficient methodological rigor in the included trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.
Figure 2
Figure 2
Risk of bias assessment.
Figure 3
Figure 3
Improvement of overall IBS-D symptoms and scores.
Figure 4
Figure 4
Improvement of specific IBS-D symptoms.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brandt L. J., Chey W. D., Foxx-Orenstein A. E., et al. An evidence-based position statement on the management of irritable bowel syndrome. American Journal of Gastroenterology. 2009;104(supplement 1):S1–S35. - PubMed
    1. Rey E., Talley N. J. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Digestive and Liver Disease. 2009;41(11):772–780. doi: 10.1016/j.dld.2009.07.005. - DOI - PubMed
    1. Hungin A. P. S., Chang L., Locke G. R., Dennis E. H., Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Alimentary Pharmacology & Therapeutics. 2005;21(11):1365–1375. doi: 10.1111/j.1365-2036.2005.02463.x. - DOI - PubMed
    1. Drossman D. A., Morris C. B., Schneck S., et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. Journal of Clinical Gastroenterology. 2009;43(6):541–550. doi: 10.1097/mcg.0b013e318189a7f9. - DOI - PMC - PubMed
    1. Ringel Y., Williams R. E., Kalilani L., Cook S. F. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology. 2009;7(1):68–72. doi: 10.1016/j.cgh.2008.07.008. - DOI - PubMed

LinkOut - more resources